NEW YORK: Growing volatility in US stocks is driving a search for defensive assets, though investors may have fewer places to hide this time around. Wall Street’s most closely-watched measure of investor nervousness, the Cboe Volatility Index, on Friday hit its highest in nearly seven months, as the S&P 500 slid for the week. The…
Read More “Wall Street investors seek shelter | The Express Tribune” »
KARACHI: The price of gold has dropped sharply in the domestic market in the wake of stern action against the mafia involved in illegal activities. Since the crackdown on illicit trade, the price of gold has come down by a whopping Rs27,000, reaching Rs188,000 per tola. The local gold pricing body has not been releasing…
Read More “Crackdown pulls down gold price sharply | The Express Tribune” »
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, putting the shot on track to be available in the U.S. this fall….
The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California. Mario Tama | Getty Images The Federal Trade Commission on Friday said it has reached a deal with drug giant Amgen to allow the company’s $27.8 billion purchase of Horizon Therapeutics to move forward. The two companies now expect…
Read More “FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisition” »
Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson’s consumer-health business, speaks during an interview to celebrate its IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan Mcdermid | Reuters Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name…
The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Medicare has agreed to pay for the Alzheimer’s treatment Leqembi, a major turning point for patients who are diagnosed with the early stages of the disease. Leqembi is the only drug on the…
Read More “Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know” »
